重组人干扰素α-2b喷雾剂(假单胞菌)治疗儿童急性上呼吸道感染的临床疗效

Clinical efficacy of recombinant human interferon α-2b spray(Pseudomonas) in treatment of children with acute upper respiratory tract infection

目的评价重组人干扰素(rhIFN)α-2b喷雾剂(假单胞菌)治疗儿童急性上呼吸道感染的临床疗效。方法选择2019年12月至2020年6月就诊于延安市人民医院的急性上呼吸道感染患儿100例,其中男性55例,女性45例;年龄1.1~5.4岁,平均年龄2.23岁;病程0.5~3.0 d,平均病程1.47 d;C反应蛋白(CRP)治疗前5.76~149.43 mg/L。随机分为试验组和对照组,各50例。对照组进行常规对症治疗,体温≥38.5℃时给予退热药物治疗,体温<38.5℃时给予物理降温。试验组在常规对症治疗基础上给予rhIFNα-2b喷雾剂治疗。观察两组临床疗效及不良反应。结果经过治疗,试验组患儿有效率为94%,明显高于对照组(62%),差异有显著统计学意义(P <0.01)。试验组完全退热时间为(36.00±13.64) h,鼻塞消失时间为(1.36±0.61) d,流涕消失时间为(1.48±0.51) d,咽痛消失时间为(1.07±0.25) d,扁桃体肿大消失时间为(1.43±0.66) d,咳嗽消失时间为(1.11±0.32) d,全身酸痛消失时间为(1.16±0.37) d,均明显短于对照组(P <0.01)。试验组患儿CRP[(6.90±3.40) mg/L]显著低于对照组CRP[(11.85±9.49) mg/L],差异有显著统计学意义(P <0.01)。结论 rhIFNα-2b喷雾剂治疗儿童急性上呼吸道感染起效快、疗效显著,有助于快速缓解发热、减轻上呼吸道症状,可以有效缩短病程。

Objective To evaluate clinical efficacy of recombinant human interferon(rhIFN) α-2 b spray(Pseudomonas) in treatment of children with acute upper respiratory tract infection. Methods From December 2019 to June 2020, 100 children with acute upper respiratory tract infection were enrolled, which included 55 males and 45 females, aged 1.1-5.4 years old with mean age of 2.23 years old;disease course was 0.5-3.0 days with mean course of 1.47 days;C-reactive protein(CRP) was5.76-149.43 mg/L before treatment. All of them were randomly divided into experimental group(n = 50) and control group(n =50). The control group received routine symptomatic treatment, and body temperature ≥ 38.5 ℃ was given antipyretic drug treatment, while body temperature < 38.5 ℃ was given physical cooling. The experimental group was given rhIFN α-2 b spray on the basis of conventional symptomatic treatment. The clinical efficacy and adverse reactions of 2 groups were observed. Results After treatment, the effective rate in experimental group was 94 %, which was significantly higher than that in control group(62 %), and the difference was statistically significant(P < 0.01). In experimental group, the disappearance time of complete antipyretic fever [(36.00 ± 13.64) hours], nasal congestion [(1.36 ± 0.61) days], nasal discharge [(1.48 ± 0.51) days], pharyngeal pain [(1.07 ± 0.25) days], tonsil enlargement [(1.43 ± 0.66) days], cough [(1.11 ± 0.32) days], and body soreness [(1.16 ±0.37) days] were significantly shorter than those in control group(P < 0.01). The CRP of experimental group[(6.90 ± 3.40) mg/L]was significantly lower than that of control group[(11.85 ± 9.49) mg/L], and the difference was statistically significant(P < 0.01).Conclusion It is demonstrated that rhIFN α-2 b spray is effective and effective for treatment of acute upper respiratory tract infection in children, which is helpful for the rapid relief of fever and symptoms of upper respiratory tract.